The cost–effectiveness of HPV vaccination in addition to screening: a Dutch perspective

References

• World Health Organization. Human Papillomavirus (HPV). April 30th. 2014. Available from: www.who.int/immunization/diseases/hpv/en/ [Last accessed on 19 Aug 2014]
   Google Scholar
• Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348:518-27
   PubMed Web of Science ®Google Scholar
• Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013;382(9895):889-99
   PubMed Web of Science ®Google Scholar
• Deligeoroglou E, Giannouli A, Athanasopoulos N. HPV infection: immunological aspects and their utility in future therapy. Infect Dis Obstet Gynecol 2013;2013:540850
   Google Scholar
• World Health Organization. Comprehensive cervical cancer prevention and control: a healthier future for girls and women. World Health Organization; Switzerland: 2013
   Google Scholar
• Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):89-99
   PubMed Web of Science ®Google Scholar
• Szarewski A, Poppe WAJ, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15?25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012;131(1):106-16
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmerón J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. The Lancet 2009;374(9686):301-14
   PubMed Web of Science ®Google Scholar
• Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70
   PubMed Web of Science ®Google Scholar
• FUTURE I/II Study Group. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341
   Google Scholar
• FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356(19):1915-27
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Castellsagué X, Garland SM, et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13(1):100-10
   PubMed Web of Science ®Google Scholar
• Van de Velde N, Boily MC, Drolet M, et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model–based analysis. J Natl Cancer Inst 2012;104(22):1712-23
   PubMed Web of Science ®Google Scholar
• Rogoza RM, Westra TA, Ferko N, et al. Cost-effectiveness of prophylactic vaccination against human papillomavirus 16/18 for the prevention of cervical cancer: Adaptation of an existing cohort model to the situation in the Netherlands. Vaccine 2009;27(35):4776-83
   PubMed Web of Science ®Google Scholar
• de Kok IMCM, van Ballegooijen M, Habbema JDF. Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands. J Natl Cancer Inst 2009;101(15):1083-92
   PubMedGoogle Scholar
• Coupé VMH, van Ginkel J, de Melker HE, et al. HPV16/18 vaccination to prevent cervical cancer in The Netherlands: model-based cost-effectiveness. Int J Cancer 2009;124(4):970-8
   PubMed Web of Science ®Google Scholar
• Luttjeboer J, Westra TA, Wilschut JC, et al. Cost–effectiveness of the prophylactic HPV vaccine: An application to the Netherlands taking non-cervical cancers and cross-protection into account. Vaccine 2013;31(37):3922-7
   PubMed Web of Science ®Google Scholar
• Westra TA, Rozenbaum MH, Rogoza RM, et al. Until which age should women be vaccinated against HPV Infection? Recommendation based on cost-effectiveness analyses. J Infect Dis 2011;204(3):377-84
   PubMed Web of Science ®Google Scholar
• Coupé VMH, de Melker HE, Snijders PJF, et al. How to screen for cervical cancer after HPV16/18 vaccination in The Netherlands. Vaccine 2009;27(37):5111-19
   Google Scholar
• Lazcano-Ponce E, Stanley M, Muñoz N, et al. Overcoming barriers to HPV vaccination: Non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014;32(6):725-32
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8(5):336-41
   PubMed Web of Science ®Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62(10):e1-e34
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS)–Explanation and Elaboration: a Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health 2013;16(2):231-50
   PubMed Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. Int J Technol Assess Health Care 2013;29(02):117-22
   Google Scholar
• Briggs A, Claxton K, Sculpher M. Decision Modelling for Health Economic Evaluation. Oxford University Press ,New York; 2011
   Google Scholar
• Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd Edition. Oxford University Press, New York; 2005
   Google Scholar
• The World Bank. inflation, consumer price (% annual). 2014. Available from: http://data.worldbank.org/indicator/FP.CPI.TOTL.ZG [Last accessed on 18 Mar 2014]
   Google Scholar
• Oostenbrink JB, Koopmanschap MA, Rutten FFH. Standardisation of costs: the Dutch Manual for Costing in Economic Evaluations. Pharmacoeconomics 2002;20(7):443-54
   PubMedGoogle Scholar
• Tan SS, Bouwmans CAM, Rutten FFH, Hakkaart-van Roijen L. Update of the Dutch Manual for Costing in Economic Evaluations. Int J Technol Assess Health Care 2012;28(02):152-8
   Google Scholar
• Coupé VMH, Bogaards JA, Meijer CJLM, Berkhof J. Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening. Vaccine 2012;30(10):1813-22
   PubMedGoogle Scholar
• Bogaards JA, Coupé VMH, Meijer CJLM, Berkhof J. The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands. Vaccine 2011;29(48):8929-36
   PubMed Web of Science ®Google Scholar
• Westra TA, Stirbu-Wagner I, Dorsman S, et al. Inclusion of the benefits of enhanced cross-protection against CC and prev of genital warts in the CEA of HPV vaccination in the Netherlands. BMC Infect Dis 2013;13:75
   Google Scholar
• de Kok IMCM, Habbema JDF, van Rosmalen J, van Ballegooijen M. Would the effect of HPV vaccination on non-cervical HPV-positive cancers make the difference for its cost-effectiveness? Eur J Cancer 2011;47(3):428-35
   PubMed Web of Science ®Google Scholar
• Seto K, Marra F, Raymakers A, Marra C. The cost-effectiveness of human papillomavirus vaccines. Drugs 2012;72(5):715-43
   PubMed Web of Science ®Google Scholar
• Koleva D, Compadri P, Padula A, Garattini L. Economic evaluation of human papilloma virus vaccination in the European Union: a critical review. Intern Emerg Med 2011;6(2):163-74
   PubMedGoogle Scholar
• Armstrong EP. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types. J Manag Care Pharm 2010;16(3):217-30
   PubMed Web of Science ®Google Scholar
• Marra F, Cloutier K, Oteng B, et al. Effectiveness and cost-effectiveness of human papillomavirus vaccine. Pharmacoeconomics 2009;27(2):127-47
   PubMedGoogle Scholar
• de Peuter MA, Littlewood KJ, Annemans L, et al. Cost–effectiveness of catch-up programs in human papillomavirus vaccination. Expert Rev Vaccines 2010;9(10):1187-201
   Web of Science ®Google Scholar
• Rebolj M, van Ballegooijen M, Berkers LM, Habbema D. Monitoring a national cancer prevention program: successful changes in cervical cancer screening in the Netherlands. Int J Cancer 2007;120(4):806-12
   Google Scholar
• Claxton K, Sculpher M, Culyer A, et al. Discounting and cost-effectiveness in NICE ? stepping back to sort out a confusion. Health Econ 2006;15(1):1-4
   Google Scholar
• World Health Organization. WHO guide for standardization of economic evaluations of immunization programmes. the WHO Document Production Services, Geneva, Switzerland 2008
   Google Scholar
• Smulders YM, Thijs A. Kostprijs per gewonnen levensjaar: trends en tegenstrijdigheden. Ned Tijdschr Geneeskd 2006;150(45):2467-70
   Google Scholar
• Jackson CH, Thompson SG, Sharples LD. Accounting for uncertainty in health economic decision models by using model averaging. J R Stat Soc Ser A Stat Soc 2009;172(2):383-404
   PubMedGoogle Scholar
• Thabane l, Mbuagbaw L, Zhang S, et al. A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol 2013;13:92
   Google Scholar
• Karnon J, Vanni T. Calibrating models in economic evaluation. Pharmacoeconomics 2011;29(1):51-62
   Google Scholar
• Baio G, Dawid AP. Probabilistic sensitivity analysis in health economics. Statistical Methods in Medical Research. 2011 September 18.
   Google Scholar
• Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 2008;26(3):191
   PubMed Web of Science ®Google Scholar
• Brisson M, Edmunds WJ. Economic evaluation of vaccination programs: the impact of herd-immunity. Med Decis Making 2003;23(1):76-82
   PubMed Web of Science ®Google Scholar
• Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994;140(2):81-104
   PubMed Web of Science ®Google Scholar
• Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective. Stat Med 1999;18(23):3263-82
   PubMed Web of Science ®Google Scholar
• Lugnér AK, Mylius SD, Wallinga J. Dynamic versus static models in cost-effectiveness analyses of anti-viral drug therapy to mitigate an influenza pandemic. Health Econ 2010;19(5):518-31
   PubMed Web of Science ®Google Scholar
• The Health Council of the Netherlands. Population screening for cervical cancer. 2011/07E ed. The Hague: Health Council of the Netherlands. 2011
   Google Scholar
• Thiry N, De Laet C, Hulstaert F, et al. Cost-effectiveness of human papillomavirus vaccination in Belgium: do not forget about cervical cancer screening. Int J Technol Assess Health Care 2009;25(02):161-70
   Google Scholar
• De Vincenzo R, Ricci C, Conte C, Scambia G. HPV vaccine cross-protection: highlights on additional clinical benefit. Gynecol Oncol 2013;130(3):642-51
   PubMed Web of Science ®Google Scholar
• Demarteau N, Tang CH, Chen HC, et al. Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan. Value Health 2012;15(5):622-31
   PubMed Web of Science ®Google Scholar
• Capri S, Gasparini R, Panatto D, Demarteau N. Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecol Oncol 2011;121(3):514-21
   Google Scholar
• Préaud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. J Med Econ 2013;16(6):763-76
   PubMedGoogle Scholar
• Crawford R, Grignon AL, Kitson S, et al. High prevalence of HPV in non-cervical sites of women with abnormal cervical cytology. BMC cancer 2011;11:473
   Google Scholar
• Burger EA, Sy S, Nygård M, et al. Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One 2014;9(3):e89974
   PubMed Web of Science ®Google Scholar
• D’Souza G, Dempsey A. The role of HPV in head and neck cancer and review of the HPV vaccine. Prev Med 2011;53(Supplement 1(0)):S5-S11
   Google Scholar
• Skinner SR, Garland SM, Stanley MA, et al. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 2008;188(4):238-42
   Google Scholar
• Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ 2001;10(7):587-99
   PubMed Web of Science ®Google Scholar
• Klock RM, Brouwer WBF, Annemans LJP, et al. Towards a healthier discount procedure. Expert Rev Pharmacoecon Outcomes Res 2005;5(1):59-63
   PubMedGoogle Scholar
• Demarteau N, Van Kriekinge G, Simon P. Incremental cost-effectiveness evaluation of vaccinating girls against cervical cancer pre- and post-sexual debut in Belgium. Vaccine 2013;31(37):3962-71
   PubMed Web of Science ®Google Scholar
• ISPOR. Pharmacoeconomic Guidelines Around The World. 2014. Available from: www.ispor.org/peguidelines/index.asp [Last accessed on 28 Mar 2014]
   Google Scholar
• Mareike S, Jurgen J. Towards a social discount rate for the economic evaluation of health technologies in Germany: an exploratory analysis. Eur J Health Econ 2012;13(2):127-44
   Google Scholar
• Vanni T, Luz PM, Foss A, et al. Economic modelling assessment of the HPV quadrivalent vaccine in Brazil: A dynamic individual-based approach. Vaccine 2012;30(32):4866-71
   Google Scholar
• Lee VJ, Tay SK, Teoh YL, Tok MY. Cost-effectiveness of different human papillomavirus vaccines in Singapore. BMC Public Health 2011;11:203
   Google Scholar
• Aponte-González J, Fajardo-Bernal L, Diaz J, et al. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One 2013;8(11):e80639
   PubMed Web of Science ®Google Scholar
• Szucs TD, Largeron N, Dedes KJ, et al. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland. Curr Med Res Opin 2008;24(5):1473-83
   PubMed Web of Science ®Google Scholar
• Mennini FS, Giorgi Rossi P, Palazzo F, Largeron N. Health and economic impact associated with a quadrivalent HPV vaccine in Italy. Gynecol Oncol 2009;112(2):370-6
   Google Scholar
• Anonychuk AM, Bauch CT, Merid MF, et al. A cost-utility analysis of cervical cancer vaccination in preadolescent Canadian females. BMC Public Health 2009;9:401
   Google Scholar
• Combrinck CE, Seedat RY, Burt FJ. FRET-based detection and genotyping of HPV-6 and HPV-11 causing recurrent respiratory papillomatosis. J Virol Methods 2013;189(2):271-6
   Google Scholar
• Soergel P, Makowski L, Schippert C, et al. The cost efficiency of HPV vaccines is significantly underestimated due to omission of conisation-associated prematurity with neonatal mortality and morbidity. Hum Vaccin Immunother 2012;8(2):243-51
   PubMed Web of Science ®Google Scholar
• Préaud E, Largeron N. Economic burden of non-cervical cancers attributable to human papillomavirus: a European scoping review. J Med Econ 2013;16(6):763-76
   PubMedGoogle Scholar
• Philips Z, Bojke L, Sculpher M, et al. Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment. Pharmacoeconomics 2006;24(4):355-71
   PubMed Web of Science ®Google Scholar
• Drummond MF, Richardson W, O’Brien BJ, et al. Guides to the medical literature: xiii. how to use an article on economic analysis of clinical practice a. are the results of the study valid? JAMA 1997;277(19):1552-7
   PubMed Web of Science ®Google Scholar
• Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014;32(14):1595-601
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001). January, 16th. 2014. Available from: http://clinicaltrials.gov/ct2/show/NCT00543543 [Last accessed on 27 Mar 2014]
   Google Scholar
• Serrano B, Alemany L, Tous S, et al. Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease. Infect Agent Cancer 2012;7(1):38
   PubMed Web of Science ®Google Scholar
• Drolet M, Laprise JF, Boily MC, et al. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine. Int J Cancer 2014;134(9):2264-8
   PubMed Web of Science ®Google Scholar
• Olsen J, Jepsen MR. Human papillomavirus transmission and cost-effectiveness of introducing quadrivalent HPV vaccination in Denmark. Int J Technol Assess Health Care 2010;26(02):183-91
   Google Scholar